Healthcare Economist February 9, 2024
Jason Shafrin

That is the topic of a recent white paper from the Innovation and Value Initiative titled “Valuing Rare Disease Treatments in Healthcare: Real Experience, Real Impact“. The report notes a number of challenges in assessing treatment value in rare disease (see my white paper “Challenges in Preserving Access to Orphan Drugs Under an HTA Framework” for a more detailed discussion of this topic). For instance, there is often a lack of consensus on the on the outcomes that need to be assessed in clinical studies, in part due to the small size of the patient population. Further, because these diseases are rare, any real world data is likely to have–by definition–a very small sample size.

  • Patient Journey and Time....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Provider
Artificial Intelligence in Healthcare: New Avenues for Liability
CEO of McLaren Bay Region steps down
AHA expresses concerns with UHG program in response to cyberattack on Change Healthcare
Blocking this protein could help prevent 40% of uterine cancer deaths
Providers losing $100M daily over Change Healthcare hack: Report

Share This Article